Colon Cancer

Title	Average Rating
Clinical Investigations on Ukrain	90.00%
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell	90.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.	90.00%
GcMAF-The cancer revolution from Japan	87.50%
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort	80.00%
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer	80.00%
Cancer Psychotherapy according to Dr. Frederick B Levenson	76.00%
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.	70.00%
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.	60.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer.	60.00%

Languages